ELV - Elevance Health Inc.
NYSE
->
Healthcare
->
Healthcare Plans
Indianapolis,
United States
Type: Equity
ELV price evolution
ELV
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | ||||
| Long term investments | ||||
| Property, plant & equipment | $4505 | $4450 | $4451 | $4359 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $116533 | $112988 | $111894 | $108928 |
| Current liabilities | ||||
| Accounts payable | $6255 | $5760 | $5658 | $6910 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $8715 | $8885 | $10133 | $1874 |
| Long term debt | $24688 | $24561 | $21976 | $23246 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $72758 | $70797 | $71286 | $69622 |
| Shareholders' equity | ||||
| Retained earnings | $35157 | $34575 | $33088 | $31749 |
| Other shareholder equity | -$659 | -$670 | -$674 | $39306 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | ||||
| Long term investments | ||||
| Property, plant & equipment | $4359 | $4316 | $4547 | $4129 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $108928 | $102772 | $97460 | $86615 |
| Current liabilities | ||||
| Accounts payable | $6910 | $5035 | $4970 | $5493 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $1874 | $6800 | $7841 | $7150 |
| Long term debt | $23246 | $22349 | $21157 | $19335 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $69622 | $66465 | $61400 | $53416 |
| Shareholders' equity | ||||
| Retained earnings | $31749 | $29724 | $27088 | $23802 |
| Other shareholder equity | $39306 | -$2503 | -$670 | -$797 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $39939 | $38632 | $38095 | $36581 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $37580 | $36281 | $35568 | $34554 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $533 | $493 | $531 | $275 |
| Interest expense | -$213 | -$208 | -$201 | -$200 |
| Net income | ||||
| Net income | $1618 | $1653 | $1805 | $1137 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $138639 | $121867 | $104260 | $92131 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $129484 | $114156 | $97480 | $86273 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $1830 | $1666 | $1178 | $1346 |
| Interest expense | -$798 | -$784 | -$746 | -$753 |
| Net income | ||||
| Net income | $6104 | $4572 | $4807 | $3750 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$4849 | -$3602 | -$1578 | -$9638 |
| Financing activities | ||||
| Dividends paid | -$924 | -$618 | -$309 | -$1104 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$1060 | $195 | $322 | $423 |
| Effect of exchange rate | -$16 | -$10 | -$4 | -$10 |
| Change in cash and equivalents | $3992 | $1576 | $1281 | -$861 |
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$9638 | -$7324 | -$2792 | -$1259 |
| Financing activities | ||||
| Dividends paid | -$1104 | -$954 | -$818 | -$776 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $423 | -$2567 | -$2266 | -$2241 |
| Effect of exchange rate | -$10 | $7 | -$2 | |
| Change in cash and equivalents | -$861 | $804 | $1003 | $325 |
News
Fundamentals
| Market cap | $93.61B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 231.93M |
| Revenue | $153.25B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $6.21B |
| Revenue Q/Q | 11.49% |
| Revenue Y/Y | N/A |
| P/E ratio | 15.07 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.61 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $26.79 |
|---|---|
| ROA | 5.52% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |